Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-TB-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
LENTI-TB-01 is a preclinical-stage, non-integrative lentiviral vector-based therapeutic vaccine candidate being developed by Theravectys for the treatment of tuberculosis. The vaccine is designed to deliver specific Mycobacterium tuberculosis antigens directly to dendritic cells in vivo, leveraging Theravectys's proprietary lentiviral vector platform. This approach aims to stimulate a robust and long-lasting cellular immune response, particularly cytotoxic T-cell activity, to eliminate infected cells and prevent disease relapse or reactivation.
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on LENTI-TB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-TB-01.